Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

S, Imafuku; M, Honma; Y, Okubo; M, Komine; M, Ohtsuki; A, Morita; N, Seko; N, Kawashima; S, Ito; T, Shima; H, Nakagawa

doi:10.1111/1346-8138.13306

Public

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

Shared by NobleBlocks on Feb 26, 2016 • 12:00 AM UTC

Authors:

Imafuku S

Honma M

Okubo Y

Abstract

Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human-recombinant anti-interleukin-17A monoclonal antibody was indicated for psoriasi...

Subject

Interleukin-17a

Secukinumab

Psoriasis Area And Severity Index

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!